18 completed. 11 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 11 |
| Phase 1 | 7 | Completed 7 |
Follow PF-06700841: new trials by email Literature Review of PF-06700841 trials Research Report on PF-06700841
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia PF-06700841, Placebo - Cicatricial Alopecia | Phase 2 | Completed | Emma Guttman | 51 | 2021-05-19 | 2026-05-19 |
| Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids PF-06700841, Ethinyl estradiol (EE) and levonorgestrel (LN) - Healthy Female Volunteers | Phase 1 | Completed | Pfizer | 18 | 2020-08-24 | 2020-11-13 |
| Renal Impairment Study of PF-06700841 PF-06700841 - Healthy Volunteer, Renal Impairment | Phase 1 | Completed | Pfizer | 30 | 2020-07-03 | 2024-01-22 |
| A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa PF-06650833, PF-06700841, PF-06826647 - Acne Inversa | Phase 2 | Completed | Pfizer | 194 | 2019-12-02 | 2023-06-15 |
| A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy Participants PF-06700841, Itraconazole - Heathy Participants | Phase 1 | Completed | Pfizer | 12 | 2019-09-24 | 2020-01-30 |
| A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis PF-06700841, Placebo - Psoriatic Arthritis | Phase 2 | Completed | Pfizer | 219 | 2019-06-13 | 2021-08-04 |
| Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis PF-06700841, Vehicle (Placebo) - Atopic Dermatitis | Phase 2 | Completed | Pfizer | 292 | 2019-05-13 | 2021-03-29 |
| A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Placebo, PF-06700841 15 mg, PF-06700841 30 mg - Systemic Lupus Erythematosus | Phase 2 | Completed | Pfizer | 350 | 2019-04-18 | 2024-09-05 |
| Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis PF-06700841, Vehicle (Placebo) - Psoriasis | Phase 2 | Completed | Pfizer | 344 | 2019-04-08 | 2022-06-29 |
| Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations PF-06700841 Immediate release tablets, PF-06700841 Modified release tablets - Healthy Participants | Phase 1 | Completed | Pfizer | 8 | 2019-01-07 | 2019-05-09 |
| A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects PF-06651600, placebo, PF06700841 - Active Non-segmental Vitiligo | Phase 2 | Completed | Pfizer | 366 | 2018-11-26 | 2022-03-25 |
| A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers PF-06700841, Placebo, moxifloxacin - Healthy | Phase 1 | Completed | Pfizer | 33 | 2018-09-05 | 2019-02-27 |
| Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease PF-06651600 Placebo, PF-06651600, Placebo PF-06700841 - Crohn's Disease | Phase 2 | Completed | Pfizer | 244 | 2018-02-02 | 2024-10-30 |
| Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers PF-06700841, Placebo - Healthy | Phase 1 | Completed | Pfizer | 8 | 2017-08-16 | 2017-10-25 |
| Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis PF-06651600 or Placebo, PF-06700841 or Placebo, PF-06700841 - Ulcerative Colitis | Phase 2 | Completed | Pfizer | 319 | 2017-02-03 | 2022-07-21 |
| Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata PF-06651600, PF-06700841, Placebo - Alopecia Areata | Phase 2 | Completed | Pfizer | 142 | 2016-12-15 | 2020-05-26 |
| Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis PF-06700841, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | Pfizer | 212 | 2016-12-01 | 2019-03-29 |
| A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation PF-06700841 oral solution/suspension, Placebo, PF-06700841 tablet - Plaque Psoriasis | Phase 1 | Completed | Pfizer | 96 | 2014-11-01 | 2017-03-08 |
Alopecia (1) · Alopecia Areata (1) · Arthritis, Psoriatic (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Dermatitis, Atopic (1) · Hidradenitis Suppurativa (1) · Lupus Erythematosus, Systemic (1) · Lymphoma, Follicular (1) · Psoriasis (1) · Renal Insufficiency (1) · Spondylarthritis (1)
Pfizer (17) · Emma Guttman (1)
United States (14) · Australia (8) · Canada (8) · Poland (7) · Belgium (6) · Germany (6) · Hungary (6) · Bulgaria (5) · Spain (5) · Czechia (4) · Italy (4) · Japan (4) · Serbia (4) · South Korea (4) · Denmark (3)
Emma Guttman, MD (1)
PMID 36045513, PMID 30113844, PMID 37917289, PMID 29266308, PMID 31972249, PMID 32311398, PMID 33687069, PMID 34863853, PMID 34915057, PMID 36370907, PMID 36623678, PMID 37194394, PMID 37777018, PMID 38141256, PMID 38263353, PMID 38335032, PMID 38627914, PMID 39023568, PMID 39160651, PMID 39461505, PMID 40560938, PMID 40654284, PMID 41852927, PMID 41917311, PMID 42081176, PMID 42481842
2018 (7), 2016 (3), 2017 (2)